{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:17Z","timestamp":1790874737053,"version":"4.1.0"},"reference-count":38,"publisher":"American Society for Clinical Investigation","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RO1AR073208"],"award-info":[{"award-number":["RO1AR073208"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1K23AR075898"],"award-info":[{"award-number":["1K23AR075898"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30-AR070254"],"award-info":[{"award-number":["P30-AR070254"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"DOI":"10.1172\/jci150201","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:00:57Z","timestamp":1642428057000},"source":"Crossref","is-referenced-by-count":62,"title":["Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence"],"prefix":"10.1172","volume":"132","author":[{"given":"David F.","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Mecoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-1702","authenticated-orcid":false,"given":"Matthew C.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0072-6939","authenticated-orcid":false,"given":"Lorinda S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-7306","authenticated-orcid":false,"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"9250","key":"B1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"B2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"issue":"2","key":"B3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"B4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"Best","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-gamma autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"B7","first-page":"990","article-title":"Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients","volume":"36","author":"Ogawa-Momohara","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"B8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"B9","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587014","article-title":"Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses","volume":"11","author":"Kidman","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/2326-6066.CIR-20-0398","article-title":"Improved T-cell receptor diversity estimates associate with survival and response to anti-PD-1 therapy","volume":"9","author":"Bortone","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"B12","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"47","key":"B13","doi-asserted-by":"crossref","first-page":"E7526","DOI":"10.1073\/pnas.1615990113","article-title":"Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer","volume":"113","author":"Xu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6167","key":"B14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"B15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-immunol-032414-112205","article-title":"Autoantigens as partners in initiation and propagation of autoimmune rheumatic diseases","volume":"34","author":"Rosen","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"B16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma","volume":"71","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol Lett"},{"issue":"4","key":"B18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"B19","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: visualization of intersecting sets","volume":"20","author":"Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"2","key":"B20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"B21","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s10067-019-04782-0","article-title":"Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study","volume":"39","author":"Sung","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"2","key":"B22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"B23","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"B26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","article-title":"Expression of the dermatomyositis autoantigen transcription intermediary factor 1\u03b3 in regenerating muscle","volume":"67","author":"Mohassel","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"157","key":"B27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004385","article-title":"Targeting cancer with a lupus autoantibody","volume":"4","author":"Hansen","year":"2012","journal-title":"Sci Transl Med"},{"issue":"11","key":"B28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-14-2278","article-title":"Optimizing a lupus autoantibody for targeted cancer therapy","volume":"75","author":"Noble","year":"2015","journal-title":"Cancer Res"},{"issue":"9","key":"B29","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.18632\/oncotarget.3376","article-title":"CARP-1\/CCAR1: a biphasic regulator of cancer cell growth and apoptosis","volume":"6","author":"Muthu","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"B30","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1074\/jbc.RA119.009898","article-title":"Antagonizing binding of cell cycle and apoptosis regulatory protein 1 (CARP-1) to the NEMO\/IKK\u03b3 protein enhances the anticancer effect of chemotherapy","volume":"295","author":"Venkatesh","year":"2020","journal-title":"J Biol Chem"},{"issue":"12","key":"B31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"B32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"B33","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kD protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"B34","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"B35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol Clin"},{"issue":"7","key":"B36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"6","key":"B37","first-page":"1048","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"B38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/150201\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T13:40:59Z","timestamp":1691070059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/150201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,18]]},"published-print":{"date-parts":[[2022,1,18]]}},"alternative-id":["10.1172\/JCI150201"],"URL":"https:\/\/doi.org\/10.1172\/jci150201","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"e150201"}}